Olipudase alfa

Phase 3

Sanofi (SNYNF)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Sphingomyelin Lipidosis

View Full Landscape

Drug Information

Target Indication

Sphingomyelin Lipidosis

Clinical Trial

NCT02004691

Last updated: 2/28/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA6/24/2022

Xenpozyme

Xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD) in paediatric and adult patients with type A/B or type B.

OrphanPRIME

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

SNYNF

Sanofi

Biotechnology•North America•NASDAQ

Related Pipeline

IrbesartanPhase 3

Atrial Fibrillation

Teriflunomide (HMR1726)Phase 3

Multiple Sclerosis

DTaP-IPV-HB-PRP~T vaccinePhase 3

Diphtheria

Insulin glargine/lixisenatide Fixed Ratio CombinationPhase 3

Type 2 Diabetes

teriflunomide HMR1726Phase 3

Multiple Sclerosis

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts